New study tests furosemide and pNGAL to predict kidney trouble in sepsis

NCT ID NCT05939245

First seen Feb 28, 2026 · Last updated Jun 23, 2026 · Updated 16 times

Summary

This completed study from Indonesia University looked at 40 ICU patients with sepsis-related acute kidney injury. Researchers compared those receiving a continuous furosemide infusion to a placebo group, measuring a blood marker called pNGAL at the start and after 48 hours. The goal was to see if pNGAL levels could predict sepsis and guide treatment. The study also tracked how long patients needed a ventilator, their ICU stay, and whether they required dialysis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY DUE TO SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Rumah Sakit Cipto Mangunkusumo

    Jakarta Pusat, DKI Jakarta, 10430, Indonesia

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

furosemide

What this could lead to

If successful, this could help doctors better predict and manage acute kidney injury in sepsis patients using a simple blood test.

What could go wrong

This is a small, early-stage study with only 40 participants. The results may not apply to all patients, and furosemide carries risks like low blood pressure.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.